Myllia Biotechnology Revenue
Biotechnology Research • 
Vienna, Vienna, Austria • 21-50 Employees
Myllia Biotechnology revenue & valuation
| Annual revenue | $2,053,320 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $6,600,000 |
| Total funding | No funding |
Key Contacts at Myllia Biotechnology
Anke Loregger-Wiesmann
Director Of R&D
Sumit Pawar
Associate Director Of R&D
Company overview
| Headquarters | Am Kanal 27, Vienna, 1110, AT |
| Phone number | +4373032327 |
| Website | |
| NAICS | 541714 |
| Keywords | Project Management, Assay Development, Drug Discovery, Flow Cytometry, Oncology, Bioinformatics, Immunology, Transcriptomics, Target Identification, Functional Genomics, Targeted Sequencing, T Cell Biology, Customized Crispr Grna Design, Early R&D, Genomics Service Provider, Pooled Crispr Screening, Single-Cell Rna Sequencing, Crispr Interference Screens, Crispr Ko Screens |
| Founded | 2018 |
| Employees | 21-50 |
| Socials |
Myllia Biotechnology Email Formats
Myllia Biotechnology uses 4 email formats. The most common is {first name}.{last name} (e.g., john.doe@myllia.com), used 45.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@myllia.com | 50% |
{first initial}.{last name} | j.doe@myllia.com | 50% |
About Myllia Biotechnology
Myllia Biotechnology combines CRISPR screening with single-cell RNA sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. We utilize the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next-generation CRISPR screens. Our powerful approach has broad applications in identifying novel drug targets or elucidating unknown mechanisms of actions (MoA) of drugs. Each screening project is customized to the specific needs of our clients and we perturb cells with CRISPR KO, CRISPR interference or CRISPR activation coupled to high-content read-outs such as fitness, FACS and single-cell transcriptomics. Notably, we offer single-cell CRISPR screens (CROP-Seq) in cancer cells and primary immune cells, including primary human T cells to support biotech and pharma companies striving to develop novel CAR-T and TCR-T cell therapeutics.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Myllia Biotechnology has 3 employees across 2 departments.
Departments
Number of employees
Funding Data
Myllia Biotechnology has never raised funding before.
Australia
South Africa
Brazil
United States
Czechia
Denmark
UkraineFrequently asked questions
4.8
40,000 users
